Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer: Prospective Observational Study
1. Hypothesis : imaging biomarkers of tumor measured by F-18 fluorodeoxyglucose (FDG) positron emission tomography(PET)/computed tomography(CT) is correlated with immune checkpoint inhibitor (ICI) treatment response and patient prognosis. 2. Purpose: To evaluate the association between metabolic imaging parameters measured by F-18 FDG PET/CT and clinical outcomes in patients with non-small cell lung cancer treated with ICIs. 3. Study subject: patients with non-small cell lung cancer who will be treated with ICIs. 4. Study design: prospective observational study 5. Intervention: F-18 FDG PET/CT
• 18 years old or over
• pathologically proven non-small cell lung cancer: adenocarcinoma or squamous cell carcinoma
• patients to be treated with immune checkpoint inhibitors (nivolumab or pembrolizumab or atezolizumab)
• ECOG performance status ≤ 2
• A person who have heard the detailed explanation of this clinical trial and are willing to voluntarily decide to participate and sign the informed consent form